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THE haemodynamic and respiratory responses caused
by i.v. administration of endothelin-1 (ET-1) (20-100
pmol/kg were studied in anaesthetized spontaneously
breathing pigs. Intravenous bolus administration of
synthetic ET-1 (40-100pmol/kg) caused a transient
decrease followed by a long-lasting increase in mean
pulmonary arterial pressure and dose dependent vasocon-
striction both in the systemic and pulmonary circulations.
The effect on pulmonary arterial pressure was biphasic,
with an initial transient fall followed by a long-lasting
dose dependent increase. A biphasic response of the
systemic mean arterial pressure was demonstrated only at
a high dose of ET-1 (100 pmol]kg). ET-1 administration
did not significantly change breathing pattern or phasic
vagal input, but caused a significant decrease in passive
compliance. Passive resistances or active compliance and
resistances of the respiratory system were not modified.
These results suggest that in the pig ET-1 is a more potent
constrictor of vascular than of bronchial smooth muscle.
The vasoconstrictor activity was greater in the pulmonary
than the systemic circulations.
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Introduction
Endothelin (ET-1), a 21 amino acid peptide
recently isolated from the culture medium of
endothelial cells, is one of the most potent
vasoconstrictors known. In isolated vascular strips
of various experimental animals, ET-1 induces a
vasoconstriction that is slow to develop and
long-lasting.
2
ET-1 administered intravenously to healthy
volunteers and pigs,
4 had a plasma half-life of about
1 min. Plasma ET-1 was cleared mainly by the
kidney, splanchnic circulation and skeletal muscle.
Despite its short plasma half-life, the systemic
administration of ET-1 to various animal species
induces a long-lasting pressure effect in vivo, an
initial pressure response, either contraction or
dilation depending on the species, followed by a
secondary vasoconstriction of longer duration.
-9
The transient hypotensive effect is thought to be
mediated by potassium channels1 and/or by ET-1
evoked release of endothelium derived relaxing
factors.1>5 ET-1 has been shown to contract
non-vascular smooth muscle cells also, including
guinea-pig tracheal and bronchial strips.16’7
In vivo potent bronchoconstrictor activity of ET-1
has been demonstrated in the guinea-pig and in the
rat. 18’19 Although the haemodynamic activity of
ET-1 has been extensively studied in various animal
species, very few studies have been performed to
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evaluate the effects of ET-1 on breathing pattern
and compliance and resistances of the respiratory
system. Thus, the aim of this investigation was to
determine the dose dependence of the haemody-
namic and respiratory effects induced by the
intravenous administration of ET-1 in the pig. The
static and dynamic activities of the tracheobronchial
tree were evaluated by studying passive and active
pulmonary compliance and resistances.
Materials and Methods
Six Large White pigs of either sex, weighing
20.5 + 0.5 kg were used. Animals were sedated
with 0.05 ml/kg 1% propionylpromazine hydro-
chloride, i.m. (Bayer Italia, Spa Milano) and
anaesthetized with thiopental sodium (15 mg/kg),
i.v., first injection, followed by continuous infusion
(9 mg/kg/h) (Farmitalia, Carlo Erba Milano). The
spontaneously breathing animals were tied down
supine and body temperature was measured with a
rectal probe and maintained at 37-38C by an
electric blanket. A tracheal cannula was inserted
into the lower portion of the extrathoracic trachea
and connected to a Fleish pneumotachoograph no.
2 to record the respiratory airflow (V) and, by
electronic integration, tidal volume (VT). A side
port of the tracheal cannula was connected to a
pressure transducer (Statham 15299) for measure-
ment of tracheal pressure (Ptr)"
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The right femoral artery was cannulated with a solution and stored at -20C in a stock solution
polyethylene catheter to monitor arterial blood of 50/g/ml. Each animal was given 20-100
pressure. The right external jugular vein was pmol/kg ET-1 injected as a bolus into the jugular
cannulated to administer ET-1. A balloon-tipped vein. The bronchoconstrictor effect of ET-1 was
catheter (Swan-Ganz 5F) was introduced into the also evaluated at the concentration of 400 pmol/kg
pulmonary artery to monitor pulmonary arterial ET-1. In all pigs, the cardiovascular and respiratory
pressure and cardiac output (CO) was evaluated by parameters were monitored before and contin-
the thermodilution technique (Cardiac Output uously after ET-1 injection for 5 min and again
Computer 701 I.L.). Systemic and pulmonary every 5min until 30min.
arterial pressure were recorded by connecting the The results are expressed as means q-S.E.M. The
catheters to a fluid filled capacitance manometer statistical significance was evaluated by paired
(Bell & Howell 4-422). All signals were recorded Student’s t-test comparing the value obtained after
simultaneously on a multichannel pen recorder (Nec ET-1 administration to the last pre-injection values.
San-ei Instruments Polygraph mod. 8K40). Difference of the values were considered statistically
After recording the spontaneous resting breath- significant at p < 0.05.
ing pattern the passive compliance was evaluated
by occluding the tracheal cannula at the end of Results inspiration and at various lung volumes during
expiration, in order to plot the passive pressure- As shown in Fig. 1A, the intravenous bolus
volume (P-V) relationships of the respiratory administration of ET-1 at 40 and 100 pmol/kg to
system. At each volume, changes in pressure were pigs caused long-lasting increases in mean pulmo-
computed after 0.5 s, a time that seemed to be nary arterial pressure (MPAP) that were statistically
sufficient to accommodate most of the stress significant at 15 min and persisted up to 30 min. In
relaxation phenomena. The resistances of the contrast, administration of 20pmol/kg ET-1 did
respiratory system (Rrs) were obtained from the not significantly atCfect MPAP. At all doses, the
rs/Crs ratio. The passive time constant of the pulmonary vasoconstriction was preceded by a
respiratory system was computed from the transient decrease in MPAP that was completely
expiratory trace flow obtained after reopening the reversed at 5 min. At 40 pmol/kg, there was a
airways closed at the end of inspiration. :rs was the statistically significant increase in total pulmonary
time interval from the peak expiratory flow to 64% vascular resistance (TPVR) (Fig. 1B).
of its decay. The resistance of the respiratory system As shown in Fig. 1C, there was a statistically
was calculated by subtracting the resistance value significant increase in mean systemic arterial
of the set-up. Active compliance (C’rs) and active pressure (MAP) only after the administration of
resistances (R’rs) of the respiratory system were 100 pmol/kg ET-1. The peptide did not signifi-
evaluated by occluding the airway at the end- cantly aect total systemic vascular resistances
expiratory lungovolume to obtain tracheal occlusion (TSVR). The administration of ET-1 did not cause
pressure. Ptr, / and VT were measured at 0.04 s any significant changes in cardiac output (CO) or
intervals after the onset of inspiration, the first stroke volume (SV)(Table 1). At 100 pmol/kg, the
during occluded inspiratory effort and the and peptide caused an increase in heart rate that was
VT during the immediately preceding spontaneous statistically significant at 100 min. ET-1 did not
inspiration. Onset of inspiration was defined as significantly change respiratory frequency, tidal
inspiratory flow and/or a negative deflection in Ptr" volume, pulmonary ventilation, inspiratory or
Timing of breathing was analysed in terms of expiratory duration of unoccluded breaths (data not
duration of inspiration and expiration for spontan- shown) at any of the doses.
eous (TI, TE) and occluded breaths obtained by As shown in Fig. 2A, 40 pmol/kg ET-1 caused
occlusion of the airway at the end-expiratory level, a significant lengthening of expiratory time of
as suggested by Miserocchi et al.2’21 The latter occluded breaths (TEo). In contrast, the lengthening
manoeuvre provides evaluation of the timing of of TIO was not statistically significant (Fig. 2B). Both
breathing in the absence of lung volume related 20 and 100 pmol/kg of the peptide had no
vagal afferents. The vagal inhibitory effect on statistically significant effect on these parameters. In
respiratory centres was evaluated as the TIo/TI ratio, control conditions the TIo/T ratio, considered to
Heart rate (HR), mean pulmonary arterial pressure be an index of phasic vagal feed-back, was greater
(MPAP), mean systemic arterial pressure (MAP), than 1 and it was not significantly changed by ET-1
total pulmonary vascular resistances (TPVR), and administration (Fig. 2C).
total systemic vascular resistances (TSVR) were also As shown in the Fig. 3A, the lower doses
evaluated. (20-40 pmol/kg) of ET-1 caused significant and
Endothelin-1 (ET-1) (Sigma Chemical Company, progressive decreases in Crs that were not
St Louis, MO, USA) was dissolved in saline correlated with increases in passive respiratory
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FIG. 1. Pulmonary and systemic vascular responses to bolus ET-1 administration, (20 pmol/kg, 40 pmol/kg, 100 pmol/kg). MPAP, mean pulmonary
arterial pressure; TPVR, total pulmonary vascular resistance; MAP, mean systemic arterial pressure" TSVR, total systemic vascular resistance. Results
are compared with last pre-injection value and expressed as means S.E.M., n 6. The asterisks indicate statistically significant differences (*p < 0.05).
The arrows indicate bolus ET-1 administration.
resistances (Fig. 3B), while 100 pmol/kg of ET-1
did not change the passive compliance or resistances
of the respiratory system (Figs 3A and B). The
active compliance (C’rs) and resistances were not
significantly affected by ET-1 administration (Figs
3C and D).
In order to demonstrate the bronchoconstrictor
activity of the peptide, ET-1 was administered to
one pig at a higher concentration (400 pmol/kg).
This dose seemed to increase active respiratory
resistances without affecting C’rs (data not shown).
On the contrary, 400 pmol/kg of ET-1 did not have
any greater effects on MPAP and TPVR than those
of 40 and 100 pmol/kg (Figs 4A and B).
Table 1. Time course of cardiovascular variables in response to i.v. administration of ET-1
Concentration
of ET- Time
(pmol/kg) (min)
HR CO SV
Mean S.E.M. Mean S.E.M. Mean S.E.M.
20
40
100
0 105 8 3.0 0.4 28 2
(control)
5 110 11 3.2 0.4 29
30 120 24 3.4 0.6 29 2
35 111 15 3 0.5 26
(control)
40 108 11 2.8 0.4 26
65 112 13 2.9 0.4 26
70 130 14 3.2 0.5 25 3
(control)
75 130 16 3.2 0.6 25 3
100 143" 9 3.2 0.5 23 3
Results are means _+S.E.M., n=6. Heart rate (HR), cardiac output (CO) and stroke volume (SV).
Results are compared with last pre-injection value. *p < 0.05.
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FIG. 2. Respiratory responses to bolus ET-1 administration (20 pmol/kg, 40 pmol/kg, 100 pmol/kg) TEo and TIo represent expiratory (panel A) and
inspiratory time (panel B) of occluded breaths. In panel C, T=o/T= is the ratio of inspiratory times of occluded and unoccluded breaths. Results are
compared with last pre-injection value and expressed as means ___S.E.M., n 6. The asterisks indicate statistically significant differences (*p < 0.05).
The arrows are as in Fig. 1.
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FIG. 3. Time-course of passive compliance (Crs) (panel A) and active compliance (C’rs) (panel C) of the respiratory system, and passive (Rrs) and
active resistance (R’rs), (panels B and D, respectively) in response to bolus ET-1 administration. Results are compared with last pre-injection value and
expressed as means -I-S.E.M., n 6. The asterisks indicate statistically significant differences (*p < 0.05). The arrows are as in Fig. 1.
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FIG. 4. Time-course of pulmonary arterial pressure (MPAP) (panel A)
and total pulmonary vascular resistance (TPVFI) (panel B) for one pig,
after ET-1 administration.
Discussion
This study examined the haemodynamic and
respiratory effects of ET-1 in anaesthetized and
spontaneously breathing pigs. The results show that
the peptide is a potent vasoconstrictor mainly for
the pulmonary circulation, and a mild bronchocon-
strictor. ET-1 bolus administration increased
pulmonary arterial pressure and vascular re-
sistances. A maximum effect was obtained at
40pmol/kg of ET-1. The failure of a higher
dose to induce more marked effects is probably due
to saturation of lung ET-1 receptors by repeated
administration of the peptide to the same animals.
After all doses there was an initial transient
vasodilation followed by a long-lasting vasocon-
striction. In the systemic vascular bed, ET-1 caused
a similar biphasic response only at 100 pmol/kg.
The biphasic vascular response has been previously
demonstrated in various animal species and
in the pig by Pernow et al.4 The long-lasting
vasoconstrictive activity may be due to irreversible
interaction of ET-1 with its specific receptors. The
greater vascularization and high density of ET-1
receptors in the lung might be responsible, at least
in part, for the greater response of the pulmonary
than of the systemic circulation.
At 100 pmol/kg significant vasoconstriction was
found in the systemic circulation. Saturation of
ET-1 binding sites in the lung by previous
administration of the peptide might reduce its
pulmonary clearance thus favouring the systemic
effect.4 The transient hypotensive effect in both the
pulmonary and systemic circulations may reflect
ET-1 induced release of such vasodilators as
NO and PGI2 .11-15
At variance with other animal species, ET-1 did
not alter cardiac activity in the pig to any
statistically significant extent. The late increase in
heart rate, not correlated with the pressure effect,
is probably due to the release of ET-1 dependent
vasoactive mediators. 11-15
The results show that ET-1 does not change the
breathing pattern or the Tr/T ratio, in the pig, but
causes a significant lengthening of TE Because the
TIo/TI ratio is an index of vagal inhibitory activity
on respiratory centres, the results show that ET-1
does not alter the vagal input, but causes a change
in the bulbo-pontine rhythm probably by reduction
of cerebral vascular flow.22’23 The decrease in Crs
was not correlated with a change in passive re-
sistances observed in pigs, which suggests that
ET-1 (20-100 pmol/kg) does not alter broncho-
motor tone but causes only a decrease in lung
distensibility, probably through increases in MPAP,
or in lung capillary permeability. The results show
that ET-1 does not statistically significantly change
C’rs and ,R’rs probably because of induction of
various compensatory mechanisms of both nervous
and vascular origin.
24
Studies have shown that ET-1 acts as a potent
bronchoconstrictor when studied in vitro16’7 or in
vivo in guinea-pigs,
a8 In contrast, our results
demonstrate that in spontaneously breathing pigs
ET-1 is a mild bronchoconstrictor. In fact,
constrictive activity on bronchial smooth muscle
was caused only by a very high dose of ET-1
(400 pmol/kg). The reason for these discrepancies
is not apparent. However, differences in ET-1
catabolism by the lungs of different animal species
might be involved.
In summary, the results suggest that the effects on
the vascular and respiratory system are different
after ET-1 is administered i.v. to spontaneously
breathing pigs. ET-1 is a more potent constrictor
of vascular than of bronchial smooth muscle. Its
vasoconstrictive effect is more marked in the
pulmonary than in the systemic vascular bed.
Pharmacological studies with selective inhibitors of
ET-1 biosynthesis or action should help to
clarify the role of ET-1 in the development of
pulmonary disease.
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